Company Filing History:
Years Active: 2015-2016
Title: Sam-Sook Sul: Innovator in Monoclonal Antibody Research
Introduction
Sam-Sook Sul is a prominent inventor based in Incheon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. With a total of 3 patents to his name, his work focuses on innovative solutions for cancer treatment.
Latest Patents
One of Sam-Sook Sul's latest patents is titled "Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof." This invention relates to human monoclonal antibodies that neutralize vascular endothelial growth factor receptors. More specifically, it involves human ScFv molecules that inhibit angiogenesis and can be used in cancer treatment. The disclosed monoclonal antibody demonstrates excellent neutralizing ability in living cells, outperforming commercially available antibodies against vascular endothelial growth factor receptors. It has shown effectiveness in neutralizing these receptors not only in humans but also in mice and rats, making it a valuable asset in anticancer research.
Career Highlights
Sam-Sook Sul is currently associated with Pharmabcine Inc., where he continues to advance his research in monoclonal antibodies. His work has the potential to significantly impact cancer therapies and improve treatment outcomes for patients.
Collaborations
Throughout his career, Sam-Sook Sul has collaborated with notable colleagues, including Jin-San Yoo and Weon-Sup Lee. These partnerships have fostered innovation and contributed to the success of his research endeavors.
Conclusion
Sam-Sook Sul is a dedicated inventor whose work in monoclonal antibody research is paving the way for new cancer treatments. His innovative approaches and collaborations highlight the importance of scientific research in addressing critical health challenges.